CO2023007146A2 - Variantes de anticuerpos bovinos - Google Patents

Variantes de anticuerpos bovinos

Info

Publication number
CO2023007146A2
CO2023007146A2 CONC2023/0007146A CO2023007146A CO2023007146A2 CO 2023007146 A2 CO2023007146 A2 CO 2023007146A2 CO 2023007146 A CO2023007146 A CO 2023007146A CO 2023007146 A2 CO2023007146 A2 CO 2023007146A2
Authority
CO
Colombia
Prior art keywords
bovine antibody
antibody variants
bovine
relates
variants
Prior art date
Application number
CONC2023/0007146A
Other languages
English (en)
Spanish (es)
Inventor
Henry Luis Campos
Sandra Ann Marie Lightle
Catherine J Strietzel
Yaqi Zhu
Gregory John Fici
Alexander Pogacsas Ruhland Bally
Prajna Shanbhogue
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CO2023007146A2 publication Critical patent/CO2023007146A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CONC2023/0007146A 2020-11-20 2023-05-30 Variantes de anticuerpos bovinos CO2023007146A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063116491P 2020-11-20 2020-11-20
PCT/US2021/060161 WO2022109313A1 (en) 2020-11-20 2021-11-19 Bovine antibody variants

Publications (1)

Publication Number Publication Date
CO2023007146A2 true CO2023007146A2 (es) 2023-06-30

Family

ID=79018979

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0007146A CO2023007146A2 (es) 2020-11-20 2023-05-30 Variantes de anticuerpos bovinos

Country Status (12)

Country Link
US (1) US20230416410A1 (https=)
EP (1) EP4247851A1 (https=)
JP (1) JP2023551194A (https=)
KR (1) KR20230110297A (https=)
CN (1) CN116615463A (https=)
AR (1) AR124130A1 (https=)
AU (1) AU2021382704A1 (https=)
BR (1) BR112023008490A2 (https=)
CA (1) CA3202089A1 (https=)
CO (1) CO2023007146A2 (https=)
MX (1) MX2023005896A (https=)
WO (1) WO2022109313A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023552456A (ja) 2020-12-07 2023-12-15 インベテックス インコーポレイテッド 治療薬の家畜動物における半減期を増加させるための組成物及びその使用方法
CN119730881A (zh) * 2022-08-05 2025-03-28 硕腾服务有限责任公司 牛抗体突变体
CN119968390A (zh) * 2022-09-02 2025-05-09 硕腾服务有限责任公司 猪抗体突变体
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
TWI633117B (zh) * 2012-09-13 2018-08-21 必治妥美雅史谷比公司 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
EP3359190A4 (en) * 2015-10-05 2020-05-06 Circle33 LLC ANTIBODIES WITH IMPROVED STABILITY ABOUT DIGESTION

Also Published As

Publication number Publication date
BR112023008490A2 (pt) 2023-12-12
WO2022109313A1 (en) 2022-05-27
JP2023551194A (ja) 2023-12-07
AU2021382704A1 (en) 2023-06-08
EP4247851A1 (en) 2023-09-27
MX2023005896A (es) 2023-07-03
US20230416410A1 (en) 2023-12-28
CA3202089A1 (en) 2022-05-27
KR20230110297A (ko) 2023-07-21
CN116615463A (zh) 2023-08-18
AU2021382704A9 (en) 2025-03-27
AR124130A1 (es) 2023-02-15

Similar Documents

Publication Publication Date Title
CO2023007146A2 (es) Variantes de anticuerpos bovinos
CO2022014695A2 (es) Variantes de anticuerpos caninos
CO2022014684A2 (es) Variantes de anticuerpos felinos
CO2023007829A2 (es) Mutaciones en regiones constantes de anticuerpos felinos
CL2024001562A1 (es) Mutaciones en regiones constantes de anticuerpos caninos.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
CO2023004102A2 (es) Variantes de anticuerpos caninos
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
EA202192101A1 (ru) Соединения и их применение
MX2022013840A (es) Polipéptidos de unión a pd-1 canina y usos de los mismos.
CO2023004107A2 (es) Variantes de anticuerpos felinos
MX2024006208A (es) Anticuerpo anti-trem2 y usos del mismo.
CO2025005164A2 (es) Péptidos inmunogénicos prame, proteínas de unión que reconocen los péptidos inmunogénicos prame y usos de los mismos
MX2024006949A (es) Combinaciones
EA202192532A1 (ru) Мирикизумаб для применения в способе лечения болезни крона
MX2025002524A (es) Mutantes de anticuerpos equinos
TR202019577U4 (tr) Abajur bağlanti aparatinda yeni̇li̇k
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
TR201820317U5 (tr) Çay kazaninda (maki̇nesi̇nde) yeni̇li̇k
TR201820310U5 (tr) Çay kazaninda (maki̇nesi̇nde) yeni̇li̇k